A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets

PURPOSE: Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-κB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets. We initiated a phase I trial of temozolomide plus bortezomib in advanced...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Su, Yingjun, Amiri, Katayoun I., Horton, Linda W., Yu, Yingchun, Ayers, Gregory D., Koehler, Elizabeth, Kelley, Mark C., Puzanov, Igor, Richmond, Ann, Sosman, Jeffrey A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3205975/
https://ncbi.nlm.nih.gov/pubmed/20028756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2087
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak